Oct 1 |
The Covid Era Tech Promises To Reinvent Cancer Treatment
|
Oct 1 |
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
|
Sep 20 |
Pfizer Advances On Its Cancer Journey
|
Sep 18 |
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
|
Sep 4 |
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
|
Jul 30 |
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
|
Jul 25 |
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
|
Jul 10 |
Mainz Biomed submits FDA breakthrough device designation for its CRC screening test
|
Jul 10 |
Mainz Biomed seeks FDA breakthrough device status for colorectal cancer test
|
Jul 9 |
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
|